Implantable venous access device associated complications in patients with hereditary angioedema

Journal of Allergy and Clinical Immunology: In Practice

Volumn 1, Issue 5, 2013, Pages 524-525

  Yoo, Seungjong M ^a   Khan, David A ^b  

^a PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; MICAFUNGIN; OXANDROLONE; STANOZOLOL;

ADULT; ANAMNESIS; ANGIONEUROTIC EDEMA; ARTICLE; CANDIDA ALBICANS; CANDIDEMIA; CASE REPORT; CATHETER COMPLICATION; CENTRAL VENOUS CATHETER; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; ENDOTRACHEAL INTUBATION; FEMALE; FEVER; FUNGUS CULTURE; GASTROINTESTINAL SYMPTOM; HUMAN; LARYNX EDEMA; LUNG INFILTRATE; NONHUMAN; PATIENT ASSESSMENT; SUPERIOR CAVA VEIN SYNDROME; TACHYCARDIA; TACHYPNEA; TREATMENT DURATION; ANGIOEDEMAS, HEREDITARY; CANDIDIASIS; SUPERIOR VENA CAVA SYNDROME; VENOUS THROMBOSIS;

ADULT; ANGIOEDEMAS, HEREDITARY; CANDIDA ALBICANS; CANDIDIASIS; COMPLEMENT C1 INHIBITOR PROTEIN; FEMALE; HUMANS; SUPERIOR VENA CAVA SYNDROME; VASCULAR ACCESS DEVICES; VENOUS THROMBOSIS;

EID: 84883452473     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.04.003     Document Type: Article

References (9)

1. Zuraw B.L., Busse P.J., White M., Jacobs J., Lumry W., Baker J., et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. NEngl J Med 2010, 363:513-522.
2. Gompels M.M., Lock R.J., Abinun M., Bethune C.A., Davies G., Grattan C., et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005, 139:379-394.
3. Maki D.G., Kluger D.M., Crnich C.J. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc 2006, 81:1159-1171.
4. Hartkamp A., van Boxtel A.J.H., Zonnenberg B.A., Witteveen P.O. Totally implantable venous access devices: evaluation of complications and a prospective comparative study of two different port systems. Neth J Med 2000, 57:215-223.
5. Fratino G., Molinari C., Parodi S., Longo S., Saracco P., Castagnola E., et al. Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Ann Oncol 2005, 16:648-654.
6. Cecinati V., Brescia L., Tagliaferri L., Giordano P., Esposito S. Catheter-related infections in pediatric patients with cancer. Eur J Clin Microbiol Infect Dis 2012, 31:2869-2877.
7. Raj A., Bertolone S., Bond S., Burnett D., Denker A. Cathlink 20: a subcutaneous implanted central venous access device used in children with sickle cell disease on long-term erythrocytapheresis-a report of low complication rates. Pediatr Blood Cancer 2005, 44:669-672.
8. Alkindi S., Matwani S., Al-Maawali A., Al-Maskari B., Pathare A. Complications of port-a-cath in patients with sickle cell disease. JInfect Public Health 2012, 5:57-62.
9. Relan A., Bakhtiari K., van Amersfoort E.S., Meijers J.C.M., Hack C.E. Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedema. BioDrugs 2012, 26:43-52.